{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:13:19Z","timestamp":1790874799111,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The ambitious goal to eliminate new pediatric HIV infections by 2030 requires accelerated prevention strategies in high-risk settings such as South Africa. One approach could be pre-exposure prophylaxis (PrEP) with broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs). The aim of our study is to define the optimal dose(s), the ideal combination(s) of bNAbs in terms of potency and breadth, and timing of subcutaneous (SC) administration(s) to prevent breast milk transmission of HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two bNAbs, CAP256V2LS and VRC07-523LS, will be assessed in a sequential and randomized phase I, single-site, single-blind, dose-finding trial. We aim to investigate the 28-day safety and pharmacokinetics (PK) profile of incrementally higher doses of these bNAbs in breastfeeding HIV-1 exposed born without HIV neonates alongside standard of care antiretroviral (ARV) medication to prevent (infants) or treat (mothers) HIV infection.<\/jats:p>\n                    <jats:p>The trial design includes 3 steps and 7 arms (1, 2, 3, 4, 5, 6 and 6b) with 8 infants in each arm. The first step will evaluate the safety and PK profile of the bNAbs when given alone as a single subcutaneous (SC) administration at increasing mg\/kg body weight doses within 96\u00a0h of birth: arms 1, 2 and 3 at doses of 5, 10, and 20\u00a0mg\/kg of CAP256V2LS, respectively; arms 4 and 5 at doses of 20 and 30\u00a0mg\/kg of VRC07-523LS, respectively. Step two will evaluate the safety and PK profile of a combination of the two bNAbs administered SC at fixed doses within 96\u00a0h of birth. Step three will evaluate the safety and PK profile of the two bNAbs administered SC in combination at fixed doses, after 3\u00a0months. Arms 1 and 6 will follow sequential recruitment, whereas randomization will occur sequentially between arms (a) 2 &amp; 4 and (b) 3 &amp; 5. Before each randomization, a safety pause will allow review of safety data of the preceding arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The results of this trial will guide further studies on bNAbs to prevent breast milk transmission of HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Protocol version<\/jats:title>\n                    <jats:p>Version 4.0 dated 15 March 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Pan African Clinical Trial Registry (PACTR): PACTR202205715278722, 21 April 2022; South African National Clinical Trial Registry (SANCTR): DOH-27\u2013062022-6058.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-024-09588-3","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T04:01:43Z","timestamp":1721448103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Ameena","family":"Goga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Ramraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logashvari","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brodie","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masefetsane","family":"Matlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terusha","family":"Chetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshmi","family":"Dassaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobubelo K.","family":"Ngandu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarylee","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishen","family":"Seocharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qondeni","family":"Ndlangamandla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qholokazi","family":"September","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nokwanda","family":"Ngcobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuri","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamon","family":"Cafun-Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kubashni","family":"Woeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesha","family":"Jeenarain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Imamdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshnee","family":"Maharajh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashmintha","family":"Ramjeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thobile","family":"Bhengu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Clarence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Van de Perre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorkild","family":"Tyllesk\u00e4r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Nagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Moles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonhlanhla N.","family":"Mkhize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Dispinseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Scarlatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the PedMAb1 clinical trial team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"issue":"2","key":"9588_CR1","doi-asserted-by":"publisher","first-page":"e1001608","DOI":"10.1371\/journal.pmed.1001608","volume":"11","author":"AL Drake","year":"2014","unstructured":"Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during Pregnancy and Postpartum and Risk of Mother-to-Child HIV Transmission: A Systematic Review and Meta-Analysis. PLoS Med. 2014;11(2):e1001608.","journal-title":"PLoS Med"},{"issue":"5","key":"9588_CR2","doi-asserted-by":"publisher","first-page":"e0125525","DOI":"10.1371\/journal.pone.0125525","volume":"10","author":"TH Dinh","year":"2015","unstructured":"Dinh TH, Delaney KP, Goga A, Jackson D, Lombard C, Woldesenbet S, et al. Impact of Maternal HIV Seroconversion during Pregnancy on Early Mother to Child Transmission of HIV (MTCT) Measured at 4\u20138 Weeks Postpartum in South Africa 2011\u20132012: A National Population-Based Evaluation. PLoS ONE. 2015;10(5):e0125525.","journal-title":"PLoS ONE"},{"issue":"4","key":"9588_CR3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/cid\/ciw792","volume":"64","author":"L Myer","year":"2017","unstructured":"Myer L, Dunning L, Lesosky M, Hsiao NY, Phillips T, Petro G, et al. Frequency of viremic episodes in HIV-infected women initiating antiretroviral therapy during pregnancy: a cohort study. Clin Infect Dis. 2017;64(4):422\u20137.","journal-title":"Clin Infect Dis"},{"key":"9588_CR4","doi-asserted-by":"publisher","first-page":"j1053","DOI":"10.1136\/bmj.j1053","volume":"9","author":"P Van de Perre","year":"2017","unstructured":"Van de Perre P, Kankasa C, Nagot N, Meda N, Tumwine JK, Coutsoudis A, et al. Pre-exposure prophylaxis for infants exposed to HIV through breast feeding. BMJ. 2017;9:j1053.","journal-title":"BMJ"},{"issue":"10281","key":"9588_CR5","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/S0140-6736(21)00570-5","volume":"397","author":"P Van de Perre","year":"2021","unstructured":"Van de Perre P, Goga A, Ngandu N, Nagot N, Moodley D, King R, et al. Eliminating postnatal HIV transmission in high incidence areas: need for complementary biomedical interventions. Lancet. 2021;397(10281):1316\u201324.","journal-title":"Lancet"},{"issue":"9","key":"9588_CR6","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.1016\/S2352-3018(19)30193-6","volume":"6","author":"M Penazzato","year":"2019","unstructured":"Penazzato M, Townsend CL, Rakhmanina N, Cheng Y, Archary M, Cressey TR, et al. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. Lancet HIV. 2019;6(9):e623\u201331.","journal-title":"Lancet HIV"},{"issue":"7524","key":"9588_CR7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nature13612","volume":"514","author":"SY Ko","year":"2014","unstructured":"Ko SY, Pegu A, Rudicell RS, Yang Z yong, Joyce MG, Chen X, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014;514(7524):642\u20135.","journal-title":"Nature."},{"issue":"1","key":"9588_CR8","doi-asserted-by":"publisher","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","volume":"15","author":"MR Gaudinski","year":"2018","unstructured":"Gaudinski MR, Coates EE, Houser KV, Chen GL, Yamshchikov G, Saunders JG, et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018;15(1):e1002493.","journal-title":"PLoS Med"},{"issue":"1","key":"9588_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1128\/JVI.01791-15","volume":"90","author":"NA Doria-Rose","year":"2016","unstructured":"Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, et al. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2016;90(1):76\u201391.","journal-title":"J Virol"},{"key":"9588_CR10","doi-asserted-by":"crossref","unstructured":"Rudicell RS, Kwon Y Do, Ko SY, Pegu A, Louder MK, Georgiev IS, et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol. 2014;88(21):12669\u201382.","DOI":"10.1128\/JVI.02213-14"},{"key":"9588_CR11","doi-asserted-by":"crossref","unstructured":"Goga A, Ramraj T, Naidoo L, Matlou M, Daniels B, Chetty T,\u00a0 et al. PedMAb1 clinical trial: Safety assessment of CAP256V2LS to prevent breastmilk HIV transmission in HIV-1 exposed uninfected neonates. 11th EDCTP Forum. Paris: 7-10 November.\u00a0BMJ Glob Health. 2023;8:A16\u20137.","DOI":"10.1136\/bmjgh-2023-EDC.38"},{"key":"9588_CR12","doi-asserted-by":"crossref","unstructured":"Cook TD, DeMets DL, editors. Introduction to Statistical Methods for Clinical Trials. London: Chapman & Hall; 2008. ISBN 9781584880271.","DOI":"10.1201\/9781420009965"},{"issue":"4","key":"9588_CR13","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/S2352-3018(23)00003-6","volume":"10","author":"S Mahomed","year":"2023","unstructured":"Mahomed S, Garrett N, Capparelli EV, Osman F, Mkhize NN, Harkoo I, et al. Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. Lancet HIV. 2023;10(4):e230\u201343.","journal-title":"Lancet HIV"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09588-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09588-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09588-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T09:02:32Z","timestamp":1732438952000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09588-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9588"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09588-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4629679\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,20]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate are described in\n                      \n                      section. In addition to the ethics approval the protocol underwent scientific review before submission to SAMRC and all documents were submitted to EDCTP.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave their consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"712"}}